Jay R. Luly
2017
In 2017, Jay R. Luly earned a total compensation of $4.3M as President and Chief Executive Officer at Enanta Pharmaceuticals, a 24% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $345,648 |
|---|---|
| Option Awards | $2,055,720 |
| Salary | $581,203 |
| Stock Awards | $1,279,980 |
| Other | $18,551 |
| Total | $4,281,102 |
Luly received $2.1M in option awards, accounting for 48% of the total pay in 2017.
Luly also received $345.6K in non-equity incentive plan, $581.2K in salary, $1.3M in stock awards and $18.6K in other compensation.
Rankings
In 2017, Jay R. Luly's compensation ranked 2,341st out of 14,666 executives tracked by ExecPay. In other words, Luly earned more than 84.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,341 out of 14,666 | 84th |
Division Manufacturing | 822 out of 5,772 | 86th |
Major group Chemicals And Allied Products | 216 out of 2,075 | 90th |
Industry group Drugs | 165 out of 1,731 | 91st |
Industry Pharmaceutical Preparations | 130 out of 1,333 | 90th |
Source: SEC filing on January 19, 2018.
Luly's colleagues
We found four more compensation records of executives who worked with Jay R. Luly at Enanta Pharmaceuticals in 2017.
News
Enanta Pharmaceuticals CEO Jay Luly's 2022 pay jumps 37% to $7.3M
January 20, 2023
Enanta Pharmaceuticals CEO Jay Luly's 2021 pay rises 2% to $5.3M
January 21, 2022
Enanta Pharmaceuticals CEO Jay Luly's 2020 pay rises 16% to $5.2M
January 21, 2021
Enanta Pharmaceuticals CEO Jay Luly's 2019 pay slips 1% to $4.5M
January 17, 2020
Enanta Pharmaceuticals CEO Jay Luly's 2018 pay rises 5% to $4.5M
January 18, 2019